10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Tuesday, July 10, 2012

Jagsonpal Pharmaceuticals Ltd:Buy/sell/growth prospects and recommendation,news and results,target and analysis,view and outlook,multibagger

Scripscan:Jagsonpal Pharmaceuticals Ltd

Story:Jagsonpal Pharma is in the business of manufacturing capsules and bulk drugs for the pharmaceutical industry – with a focus on supplying solutions for lifestyle-related diseases (diabetes, blood pressure etc.)Jagsonpal Pharmaceuticals net profit rose 141.03% to Rs 0.94 crore in the quarter ended March 2012 as against Rs 0.39 crore during the previous quarter ended March 2011. Sales rose 30.13% to Rs 41.46 crore in the quarter ended March 2012 as against Rs 31.86 crore during the previous quarter ended March 2011. For the Audited full year,net profit rose 3.90% to Rs 7.46 crore in the year ended March 2012 as against Rs 7.18 crore during the previous year ended March 2011. Sales rose 9.66% to Rs 176.51 crore in the year ended March 2012 as against Rs 160.96 crore during the previous year ended March 2011.The company hasn’t really grown its revenues over the last five years but generated consistent operating profits – reporting about 13cr in operating profits on 176cr of revenues in the last financial year.It operated with modest debt of 29cr (as at 31st March, 201).The company is exposed to risks of price controls on the end products, high competition in an undifferentiated product category, falling behind on innovative and more effective drugs, and stringent supplier demands.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner